



Patent Application Attorney Docket No.PC25578A

I hereby cer	ntify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed
to: Hon. Co	ommissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this 17 day of May, 2004.
Ву	Kelly & Smith
	(Signature of person mailing) Kelly A. Smith
-	Kelly A. Smith
	(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Katharine Helen Banner, et al. :

APPLICATION NO.: 10/774,823 : Examiner:

FILING DATE: February 9, 2004 : Group Art Unit:

TITLE: ANIMAL MODEL FOR INFLAMMATORY

BOWEL DISEASE

Hon. Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97 (b)

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a).

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

Patent Application Attorney Docket No.PC25578A

A prompt and favorable response is earnestly solicited.

to: 5/11/04

Respectfully submitted,

Christine S. Lee

Attorney for Applicant(s)

Reg. No. 42,788

Pfizer Inc.

Patent Department, MS 8260-1611 Eastern Point Road Groton, Connecticut 06340 (860) 686-2144 MAY 1 3 2004 SEEDED

TANFORM	AATION [ISCLOS	URE CI	TATION	AT	TY. DOC	KET NO	D. PC255	 78A	SEF	RIAL NO	. 10/77	4.823		
	e several					PLICAN'			elen Banner, e						
				• ,	FIL	ING DA		uary 9, 20			OUP				
					U.S	. PATEN	IT DOC	UMENTS							
EXAMINER INITIAL				CUMENT NUN	MBER			DATE	NAME		CLASS SUBCLASS		FIUNG DATE IF APPROPRIATE		
	. 1		_L	<u> </u>	FORE	IGN PAT	ENT DO	CUMEN	TS		!	I			
. "			CUMENT N	LIMBER				DATE	COUNTRY		CLASS	SUBCLASS	TRANS	LATION	
DOCUMENT NUMBER												00202.55	YES	NC	
	<u> </u>						 								
		OTH	IER DO	CUMEN	TS (In	cludina A	uthor 7	itle Date	Pertinent Pa	nes	Etc.)				
	T 1							, Date,		-					
	Sa	llack, B., et	t al., "Ulce	rative Coli	tis-like C	Disease in I	Mice with a	a Disrupted	Interleukin-2 Ger	ne", Ce	ell, Vol. 75,	pp. 253-261	(1993)	
	Kul	nn, R., et al	., "Interleu	ıkin-10-De	ficient M	lice Develo	p Chronic	Enterocoliti	s", Cell, Vol. 75,	pp.263	3-274 (199	74 (1993)			
Shull, M., et al., "Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal Nature, Vol. 359, pp. 693-699 (1992)						nultifocal in	al inflammatory disease",								
		Rudolph, U., et al., "Ulcerative colitis and adenocarcinoma of the colon in Ga _{iz} -deficient mice", Nature Genetics, Vol. 10, pp. 143-150 (1995)													
	Mombaerts, P., et al., "Spontaneous Development of Inflammatory Bowel Disease in T Cell Receptor Mutant Mice", Cell, Vol. 75, pp 275-282 (1993)														
	Dianda, L., et al., "T Cell Receptor-αβ-Deficient Mice Fail to Develop Colitis in the Absense of a Microbial Environment", Am. J. Pathol., Vol. 150, No. 1, pp. 91-97 (1997)														
	Taurog, J., et al, "The Germfree State Prevents Development of Gut and Joint Inflammatory Disease in <i>HLA-B27</i> Transgenic Rats", J. Exp. Med., Vol. 180, pp. 2359-2365 (1994)														
Panwala, C., et al., "A Novel Model of Inflammatory Bowel Disease: Mice Deficient for the Multiple Drug F Spontaneously Develop Colitis", J. Immunol., 161, pp. 5733-5744 (1998) MacDonald, T., et al., "Breakdown of tolerance to the intestinal bacterial flora in inflammatory bowel disea Immunol., Vol. 102, pp. 445-447 (1995)						Drug Res	stance Gene	e, mdr	1 a,						
						el disease	(IBD)", Clin.	Ехр.							
		shimo, H., 6 (1996)	et al., "Imp	paired Defe	ense of I	ntestinal M	lucosa in l	Mice Lacking	Intestinal Trefo	il Facto	or", Scienc	e, Vol. 274,	pp. 26	2-	
		miston, M., 270, pp. 1			y Bowel	Disease a	nd Adenor	nas in Mice	Expressing a Do	minan	t Negative	N-Cadherin	", Scier	nce,	
		op, J., et al sues", Mol.						Genes are	Expressed in a T	issue-	Specific M	anner in Nor	mal Mo	ouse	
		tesman, M. 385-427 (1		liochemisti	ry of Mu	ltidrug Res	istance M	ediated by th	ne Multidrug Trar	nsporte	er", Annu. I	Rev. Biocher	n., Vol	. 62,	

OIPE JOY	23
MAY 1 3 2004	COFFICE
SPIRAT & TRAFF	S/ DRM

FORMATIC	ON DISCLOSURE CITATION	ATTY. DOCKET N	IO. PC25578A	SERIAL NO.	10/774,823				
	reral sheets if necessary)	APPLICANT Katharine Helen Banner, et al.							
		FILING DATE Fet	oruary 9, 2004	GROUP					
	Bommhardt, U., et al., "Heterogeneity with surface phenotype and effector f				T cells: correlation				
	Schinkel, A., et al., "Disruption of the Increased Sensitivity to Drugs", Cell.,	e Mouse <i>mdria</i> P-Glycoprotein Gene Leads to a Deficiency in the Blood-Brain Barrier and to ., Vol. 77, pp. 491-502 (1994)							
	Avendano, C., et al., "Inhibitors of Mu	Itidrug Resistance to An	titumor Agents (MDR)", Curr.	Med. Chem., Vol. 9,	pp 159-193 (2002				
	Altschul, S., et al., "Gapped BLAST a 25, No. 17, pp. 3389-3402 (1997)	nd PSI-BLAST: a new g	eneration of protein database	search programs", f	Nucl. Acids Res., V				
	Bradford, M., "A Rapid and sensitive Dye Binding", Analyt. Biochem., Vol.		ion of Microgram Quantities of	Protein Utilizing the	Principle of Prote				
	Banner, K.H., et al., "Characterisation A-693 (2001)	n of Spontaneous Colitis	in the mdr1a-deficient (mdr1a-	-/-) Mouse", Gastroe	nterology, Vol. 120				
		-			-				
AMINER	•	DATE	CONSIDERED						

Conforms with FORM PTO-F8-A820 INFORMATION DISCLOSURE